Eczema
Drugs: TREMFYA
- Safetyreportversion
- 1
- Safetyreportid
- 27325203
- Primarysourcecountry
- US
- Occurcountry
- US
- Transmissiondateformat
- 102
- Transmissiondate
- 20261008
- Reporttype
- 1
- Serious
- 2
- Seriousnessdeath
- 2
- Seriousnesslifethreatening
- 2
- Seriousnesshospitalization
- 2
- Seriousnessdisabling
- 2
- Seriousnesscongenitalanomali
- 2
- Seriousnessother
- 2
- Receivedateformat
- 102
- Receivedate
- 20260930
- Receiptdateformat
- 102
- Receiptdate
- 20260930
- Fulfillexpeditecriteria
- 2
- Companynumb
- US-JNJFOC-20260934578
- Primarysource
- Reportercountry
- US
- Qualification
- 3
- Sender
- Sendertype
- 6
- Senderorganization
- JOHNSON AND JOHNSON
- Receiver
- Receivertype
- 6
- Receiverorganization
- FDA
- Patient
- Reaction
- Reactionmeddraversionpt
- 29.0
- Reactionmeddrapt
- Eczema
- Reactionoutcome
- 6
- Drug
- Drugcharacterization
- 1
- Medicinalproduct
- TREMFYA
- Drugauthorizationnumb
- 761061
- Drugseparatedosagenumb
- 1
- Drugdosageform
- Unknown
- Drugindication
- Psoriasis
- Actiondrug
- 5
- Drugrecurreadministration
- 3
- Drugadditional
- 3
- Activesubstance
- Activesubstancename
- GUSELKUMAB
- Drugcharacterization
- 1
- Medicinalproduct
- TREMFYA
- Drugauthorizationnumb
- 761061
- Actiondrug
- 5
- Drugrecurreadministration
- 3
- Drugadditional
- 3
- Activesubstance
- Activesubstancename
- GUSELKUMAB
- Drugcharacterization
- 1
- Medicinalproduct
- TREMFYA
- Drugauthorizationnumb
- 761061
- Actiondrug
- 5
- Drugrecurreadministration
- 3
- Drugadditional
- 3
- Activesubstance
- Activesubstancename
- GUSELKUMAB
- Drugcharacterization
- 1
- Medicinalproduct
- TREMFYA
- Drugauthorizationnumb
- 761061
- Actiondrug
- 5
- Drugrecurreadministration
- 3
- Drugadditional
- 3
- Activesubstance
- Activesubstancename
- GUSELKUMAB
